TCR001-201

TCR001-201 Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumor

Study Name:
TCR001-201 Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors

Targeted Disease(s):
Lung Cancer

Purpose of Study:

To evaluate the objective response rate (ORR) (RECIST and iRECIST criteria) of subjects with solid cancers who receive TCR-T cell drug product, define the incidence of dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of T-Cell Receptor T cells, and evaluate the feasibility of TCR-T cell drug product manufacturing.

Study Dates:
January 1, 2022 - January 1, 2025

Study Design:
Controlled Design

Study Location:
TX

Lead Institution:
MD Anderson Cancer Center

Funding Source:
Alaunos Therapeutics

Contact:

Phone: 855-552-5389
Email: [email protected] 

ClinicalTrails.gov Identifier:
NCT05194735

Register for Trial
Freedom From Smoking Clinic
Detroit, MI | May 29, 2024
Asthma Basics Workshop - National
, | Jun 18, 2024